Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090461 · ClinicalTrials.gov registry record
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
A clinical trial, sponsored by Currax Pharmaceuticals.
- Completed
- Registry status
- 31,889
- Enrollment target
NCT06090461 is a clinical trial that has completed, run by Currax Pharmaceuticals. The registered enrollment target is 31,889 participants.
The verdict
NCT06090461 has completed, sponsored by Currax Pharmaceuticals.
- COMPLETED
- Registry status
- 31,889 participants
- Enrollment target
Study Summary
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess the cardiovascular safety of CONTRAVE® and all combined use of naltrexone and bupropion (NB) in usual clinical practice.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31,889 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090461
The ClinicalTrials.gov registry entry for NCT06090461 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31,889 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Currax Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06090461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06090461 about?
NCT06090461 is a clinical study titled "Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)". The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S. In this protocol, the investigators propose to generate real-world evidence (RWE) from electronic health records (EHR) and linked claims data to assess ...
What is the current status of trial NCT06090461?
This trial is currently completed. The enrollment target is 31,889 participants. The study started on 2014-09. Estimated completion is 2022-12.
Who is sponsoring clinical trial NCT06090461?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.